NewLink Genetics to Present Data on Cancer Immunotherapy Programs at the American Society of Clinical Oncology 2013 Annual Meeting
5/16/2013 12:04:05 PM
More...
|
NewLink Genetics Reports First Quarter 2013 Financial Results
5/6/2013 11:07:20 AM
More...
|
NewLink Genetics to Present at the Needham and Company 12th Annual Healthcare Conference
4/25/2013 7:32:05 AM
More...
|
NewLink Genetics Presents Preclinical Data on New IDO Pathway Inhibitor, NLG919, at American Association for Cancer Research 2013 Annual Meeting
4/8/2013 6:18:06 AM
More...
|
NewLink Genetics Presents Preclinical Data on NLG919, a New Drug Candidate From a Novel Class of IDO Pathway Inhibitors for the Treatment of Cancer
4/4/2013 9:30:45 AM
More...
|
NewLink Genetics Initiates Phase 2 Trial of IDO Pathway Inhibitor, Indoximod, for the Treatment of Metastatic Breast Cancer
4/2/2013 9:35:41 AM
More...
|
NewLink Genetics Reports Fourth Quarter and Full-Year 2012 Financial Results
2/28/2013 9:02:39 AM
More...
|
NewLink Genetics Announces Timing of Fourth Quarter and Year-End 2012 Financial Results Conference Call
2/26/2013 8:26:40 AM
More...
|
NewLink Genetics Announces Exercise of Underwriters' Option and Closing of Public Offering of Common Stock
2/4/2013 10:26:19 AM
More...
|
NewLink Genetics Announces Pricing of Public Offering of Common Stock
1/30/2013 9:49:08 AM
More...
|
|